Biofabrication is moving from breakthrough science to real-world impact. Across New Hampshire, New England, and the broader regenerative medicine ecosystem, researchers, companies, hospitals, and manufacturers are advancing technologies that could transform how we repair tissue, treat disease, manufacture cells, and produce lifesaving therapies.
On this page, explore recent biofabrication news stories, research breakthroughs, and industry milestones that show how this emerging field is becoming real from manufactured red blood cells and engineered tissues to bioprinting, regenerative medicine, organ replacement, and workforce training in Manchester’s Millyard.
ReGen Valley breaks ground on workforce training center in Manchester
Manchester’s Millyard is becoming a hub for regenerative manufacturing. ARMI | BioFabUSA marked the next phase of ReGen Valley with the groundbreaking of a new workforce training center, reinforcing New Hampshire’s role in building the infrastructure, talent, and partnerships needed for the emerging bioeconomy.
Safi Biotherapeutics and ARMI | BioFabUSA scale manufactured red blood cells
Safi Biotherapeutics and ARMI | BioFabUSA announced the successful technical transfer of Safi’s 10-liter manufactured red blood cell production system. The milestone moves Safi closer to producing stem-cell-derived red blood cells at clinically meaningful scale for potential civilian and military transfusion needs.
Wyss Institute leads ARPA-H project to engineer transplant-ready liver tissue
A Wyss Institute-led team received support through ARPA-H’s PRINT program to build the technological foundation for off-the-shelf engineered liver grafts. The project brings together researchers from Harvard’s Wyss Institute, MIT, the University of Colorado Boulder, and Columbia to develop vascularized, functional liver tissue using stem cells, bioreactors, immunoengineering, and 3D printing technologies.
United Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for Bioengineered Liver Support
United Therapeutics announced that the FDA granted Regenerative Medicine Advanced Therapy designation to miroliverELAP, an investigational external liver assist product for acute liver failure. The system uses a single-use bioengineered liver sustained outside the body to provide temporary liver support, manufactured by seeding a decellularized porcine liver scaffold with human endothelial and liver cells.
